Inclusion Criteria:

          -  Patients must be women with newly diagnosed histologically proven invasive carcinoma
             of the breast with no evidence of metastases, staged as per site standard of care.

          -  Patients must have been treated by BCS or mastectomy with clear margins of excision.
             Post-mastectomy positive margins for invasive disease and/or DCIS is not allowed.
             Multifocal disease (i.e. the presence of two or more foci or breast cancer within the
             same breast quadrant) and multicentric disease (i.e. the presence of two or more foci
             of breast cancer in different quadrants of the same breast) are allowed.

          -  Patients with T3N0 disease are eligible.

          -  Patients with disease limited to nodal micrometastases are not eligible

          -  Patients with nodal macrometastases (>2mm) treated by axillary dissection must have
             1-3 positive axillary nodes (macrometastases, > 2 mm).

          -  Patients treated by mastectomy and SLNB alone must have only 1 positive axillary node
             (macrometastases, > 2 mm).

          -  Patients must be ER ≥ 1% and HER2 negative on local testing

          -  Patients must have an Oncotype DX recurrence score </=25 obtained from testing of
             breast tumour tissue from a core biopsy or from the surgical specimen.

          -  Patient must consent to provision of, and investigator(s) must agree to submit to the
             CCTG Central Tumour Bank, a representative formalin fixed paraffin block of tumour
             tissue in order that the specific correlative marker assays described in the protocol
             may be conducted

          -  Patient must consent to provision of samples of blood in order that the specific
             correlative marker assays described in the protocol may be conducted.

          -  Patients must have had endocrine therapy initiated or planned for ≥ 5 years.
             Premenopausal women will receive ovarian ablation plus aromatase inhibitor therapy or
             tamoxifen if adjuvant chemotherapy was not administered. For all patients, endocrine
             therapy can be given concurrently or following RT.

          -  Patients may or may not have had adjuvant chemotherapy.

          -  RT must be administered within 16 weeks of definitive surgery if the patient is not
             treated with chemotherapy. If adjuvant chemotherapy is given, RT must begin within 12
             weeks after the last dose. (Note: adjuvant chemotherapy may be ongoing at the time of
             randomization). Definitive surgery is defined as the last breast cancer-related
             surgery.

          -  Patient's ECOG performance status must be 0, 1 or 2.

          -  Patient's age must be ≥ 35 years.

          -  For the first 736 eligible English or French-speaking subjects who have agreed to
             optional questionnaire completion: Patient is able (i.e. sufficiently fluent) and
             willing to complete the quality of life, health utilities and lost productivity
             questionnaires in either English or French

          -  Patient consent must be appropriately obtained in accordance with applicable local and
             regulatory requirements

          -  Patients must be accessible for treatment and follow-up. Investigators must assure
             themselves the patients randomized on this trial will be available for complete
             documentation of the treatment, adverse events, and follow-up.

          -  In accordance with CCTG policy, protocol treatment is to begin within 3 weeks of
             patient randomization.

          -  Women of childbearing potential must have agreed to use an effective contraceptive
             method. A woman is considered to be of "childbearing potential" if she has had menses
             at any time in the preceding 12 consecutive months.

        Exclusion Criteria:

          -  Patients with nodal disease limited to isolated tumour cells (pN0i+ < 0.2 mm).

          -  Patients with pT3N1 and pT4 disease (Note: patients with T3N0) are eligible.

          -  Any prior history, not including the index cancer, of ipsilateral invasive breast
             cancer or ipsilateral DCIS treated with radiation therapy. (Patients with synchronous
             or previous ipsilateral LCIS are eligible.)

          -  Synchronous or previous contralateral invasive breast cancer. (Patients with
             contralateral DCIS are eligible unless previously treated with radiation.)

          -  History of non-breast malignancies except adequately treated non-melanoma skin
             cancers, in situ cancers treated by local excision or other cancers curatively treated
             with no evidence of disease for ≥ 5 years.

          -  Patients who are pregnant.

          -  Patients that have had prior ipsilateral chestwall/thoracic radiation.

          -  Patients treated with chemo or endocrine therapy administered in the neoadjuvant
             setting for breast cancer. Endocrine therapy exposure 12 weeks or less prior to
             surgery is permitted.

          -  Patients with serious non-malignant disease (e.g. cardiovascular, scleroderma etc.)
             which would preclude RT.

          -  Patients with any serious active or co-morbid medical conditions, laboratory
             abnormality, psychiatric illness, active or uncontrolled infections, or serious
             illnesses or medical conditions that would prevent the patient from participating or
             to be managed according to the protocol (according to investigator's decision).